Breaking Finance News

Zacks Investment Research downgraded Merck & Co., Inc. (NYSE:MRK) to Hold in a report released today.

Zacks Investment Research has downgraded Merck & Co., Inc. (NYSE:MRK) to Hold in a report released on 10/17/2016.

Previously on 10/14/2016, Zacks Investment Research reported on Merck & Co., Inc. (NYSE:MRK) increased the target price from $0.00 to $70.00. At the time, this indicated a possible upside of 0.12%.

Just yesterday Merck & Co., Inc. (NYSE:MRK) traded -1.00% lower at $62.14. Merck & Co., Inc.’s 50-day moving average is $62.53 and its 200-day moving average is $58.84. The last closing price is up 4.56% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 13,054,599 shares of MRK traded hands, up from an average trading volume of 10,202,800

Recent Performance Chart

Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. has 52 week low of $47.97 and a 52 week high of $64.86 with a PE ratio of 33.75 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 20 brokers have issued a research note on the company. The average stock price target is $61.60 with 2 brokers rating the stock a strong buy, 7 brokers rating the stock a buy, 13 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Company's animal health products are sold to veterinarians, distributors and animal producers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.